Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 230

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 230
---
 resolution with Yissum that preserves its right to exercise the option, or if the Company ultimately elects not to exercise
the option based on the results of the large animal study, our development pipeline would exclude the Nano-Candesartan product candidate.
Such an outcome may require the Company to evaluate whether the carrying value of intangible assets associated with the ARB program should
be impaired.

<div align='center'>F-44

[RESALE PROSPECTUS ALTERNATE PAGE]</div>

The information in this Prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

| PRELIMINARY 
 PROSPECTUS  | SUBJECT       
 TO COMPLETION | DATED                   
 DECEMBER         , 2025 |

<div align='center'>REVIUM RX.

Up to 37,625,790 Shares of Common Stock</div>

This Resale Prospectus
relates to the resale, from time to time, of up to an aggregate of 37,625,790 shares of our Common Stock, including 6,372,265 shares
of Common Stock issuable upon exercise of Investor Warrants. by the Selling Stockholders identified in this Resale Prospectus under the
caption “Selling Stockholders.” We are not selling any shares of our Common Stock under this Resale Prospectus, and we will
not receive any proceeds from the sale of Shares of Common Stock offered hereby by the Selling Stockholders, although we may receive
$7,413,436 from the exercise of the outstanding Investor Warrants, if they are exercised for cash.

Until our Common Stock
is quoted on the OTCQX or the OTCQB marketplace of OTC Market or until the shares of our Common Stock are listed on a national securities
exchange, the Company and the Selling Stockholders, or their respective transferees, pledgees, données or other successors-in-interest,
may sell their Shares pursuant to this Prospectus at a fixed price per share of $1.00. Notwithstanding our belief that upon the effective
date of this registration statement our Common Stock will satisfy the admission requirements for the OTCQB and our intention to make
application for quotation on the OTCQB Market, we cannot assure you that our Common